BidaskClub lowered shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from a buy rating to a hold rating in a research note published on Friday, BidAskClub reports.

Several other research firms have also weighed in on DRNA. Cowen restated a buy rating on shares of Dicerna Pharmaceuticals in a research note on Monday, November 18th. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a hold rating to a buy rating and set a $24.00 price objective on the stock in a research note on Tuesday, January 7th. ValuEngine lowered shares of Dicerna Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, December 3rd. SunTrust Banks boosted their price objective on shares of Dicerna Pharmaceuticals from $20.00 to $24.00 and gave the stock a buy rating in a research note on Monday, November 18th. Finally, B. Riley boosted their price objective on shares of Dicerna Pharmaceuticals from $24.00 to $30.00 and gave the stock a buy rating in a research note on Thursday, January 9th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $30.63.

Dicerna Pharmaceuticals stock opened at $18.94 on Friday. The firm has a market capitalization of $1.32 billion, a PE ratio of -12.88 and a beta of 2.40. The company’s 50-day moving average is $22.54 and its 200-day moving average is $17.85. Dicerna Pharmaceuticals has a fifty-two week low of $9.39 and a fifty-two week high of $27.68.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.15). The firm had revenue of $8.04 million for the quarter, compared to analyst estimates of $11.70 million. Dicerna Pharmaceuticals had a negative return on equity of 58.92% and a negative net margin of 541.24%. Sell-side analysts anticipate that Dicerna Pharmaceuticals will post -1.28 earnings per share for the current fiscal year.

In related news, COO James B. Weissman sold 15,000 shares of the company’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $18.00, for a total value of $270,000.00. Following the transaction, the chief operating officer now owns 29,704 shares in the company, valued at approximately $534,672. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO James B. Weissman sold 20,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $26.00, for a total transaction of $520,000.00. Following the completion of the transaction, the chief operating officer now owns 34,704 shares in the company, valued at approximately $902,304. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,264,096 shares of company stock worth $123,462,978. 21.28% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in DRNA. Bank of Montreal Can acquired a new position in Dicerna Pharmaceuticals in the 2nd quarter valued at about $68,000. Charles Schwab Investment Management Inc. grew its stake in Dicerna Pharmaceuticals by 0.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 302,337 shares of the biopharmaceutical company’s stock valued at $4,762,000 after buying an additional 1,881 shares during the last quarter. Northern Trust Corp boosted its holdings in Dicerna Pharmaceuticals by 3.7% in the 2nd quarter. Northern Trust Corp now owns 683,682 shares of the biopharmaceutical company’s stock valued at $10,768,000 after purchasing an additional 24,348 shares during the period. Vanguard Group Inc. boosted its holdings in Dicerna Pharmaceuticals by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 2,339,194 shares of the biopharmaceutical company’s stock valued at $36,842,000 after purchasing an additional 35,905 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Dicerna Pharmaceuticals by 11.0% in the 2nd quarter. AQR Capital Management LLC now owns 39,643 shares of the biopharmaceutical company’s stock valued at $624,000 after purchasing an additional 3,919 shares during the period. Institutional investors and hedge funds own 84.92% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Read More: Different Types of Derivatives

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.